{
  "pmcid": "PMC11603346",
  "pmid": "39604537",
  "title": "Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis",
  "overall_score": 0.5147075917106122,
  "num_benchmarks": 3,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 12,
        "items": [
          {
            "variant": "CYP2B6*1",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Meta-analysis of 3 African studies (106 ARVDILI cases, 689 controls among 795 PLHIV) showed that CYP2B6*1/*6 heterozygotes had increased risk of efavirenz-induced liver injury versus CYP2B6*1/*1 (OR 1.83, 95% CI 1.15\u20132.90, P=0.01).",
              "Sentence": "Genotype CYP2B6*1/*6 Is Associated with increased susceptibility to efavirenz-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The pooled effects of *CYP2B6* polymorphisms on EFV-induced liver injury occurrences in PLHIV are summarized in Table [2](#Tab2) and illustrated in Fig. [2](#Fig2). Compared with normal metabolizers, *CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15\u20132.90), 2.48 (1.28\u20134.79), and 1.94 (1.24\u20133.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "| Efavirenz-induced liver injury |  |  |  |  |  |  |  |  |  |  |  |\n| *1/*6 | 0 | 0.53 | Fixed | 55 | 292 | 34 | 319 | 700 | 3 | 1.83 | 1.15\u20132.90 | 0.01 |",
                "Our findings demonstrated that a genotype known as *CYP2B6*6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*6",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2B6*6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Meta-analysis of 3 African studies (106 ARVDILI cases, 689 controls among 795 PLHIV) showed that CYP2B6*1/*6 heterozygotes had increased risk of efavirenz-induced liver injury versus CYP2B6*1/*1 (OR 1.83, 95% CI 1.15\u20132.90, P=0.01).",
              "Sentence": "Genotype CYP2B6*1/*6 Is Associated with increased susceptibility to efavirenz-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The pooled effects of *CYP2B6* polymorphisms on EFV-induced liver injury occurrences in PLHIV are summarized in Table [2](#Tab2) and illustrated in Fig. [2](#Fig2). Compared with normal metabolizers, *CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15\u20132.90), 2.48 (1.28\u20134.79), and 1.94 (1.24\u20133.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "| Efavirenz-induced liver injury |  |  |  |  |  |  |  |  |  |  |  |\n| *1/*6 | 0 | 0.53 | Fixed | 55 | 292 | 34 | 319 | 700 | 3 | 1.83 | 1.15\u20132.90 | 0.01 |",
                "Our findings demonstrated that a genotype known as *CYP2B6*6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*1",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Meta-analysis of 3 African studies showed CYP2B6*6/*6 homozygotes had increased risk of efavirenz-induced liver injury versus CYP2B6*1/*1 (OR 2.48, 95% CI 1.28\u20134.79, P=0.007).",
              "Sentence": "Genotype CYP2B6*6/*6 Is Associated with increased susceptibility to efavirenz-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe pooled effects of *CYP2B6* polymorphisms on EFV-induced liver injury occurrences in PLHIV are summarized in Table [2](#Tab2) and illustrated in Fig. [2](#Fig2). Compared with normal metabolizers, *CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15\u20132.90), 2.48 (1.28\u20134.79), and 1.94 (1.24\u20133.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).\u201d",
                "\u201cOur findings demonstrated that a genotype known as *CYP2B6*6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV.\u201d",
                "\u201cEfavirenz-induced liver injury \u2026 *6/*6 \u2026 Fixed \u2026 17 \u2026 78 \u2026 34 \u2026 319 \u2026 448 \u2026 3 \u2026 2.48 \u2026 1.28\u20134.79 \u2026 0.007\u201d (Table 2, row \u201c*6/*6\u201d under \u201cEfavirenz-induced liver injury\u201d, comparing CYP2B6 *6/*6 with CYP2B6 *1/*1)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*6",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2B6*6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Meta-analysis of 3 African studies showed CYP2B6*6/*6 homozygotes had increased risk of efavirenz-induced liver injury versus CYP2B6*1/*1 (OR 2.48, 95% CI 1.28\u20134.79, P=0.007).",
              "Sentence": "Genotype CYP2B6*6/*6 Is Associated with increased susceptibility to efavirenz-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cThe pooled effects of *CYP2B6* polymorphisms on EFV-induced liver injury occurrences in PLHIV are summarized in Table [2](#Tab2) and illustrated in Fig. [2](#Fig2). Compared with normal metabolizers, *CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15\u20132.90), 2.48 (1.28\u20134.79), and 1.94 (1.24\u20133.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).\u201d",
                "\u201cOur findings demonstrated that a genotype known as *CYP2B6*6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV.\u201d",
                "\u201cEfavirenz-induced liver injury \u2026 *6/*6 \u2026 Fixed \u2026 17 \u2026 78 \u2026 34 \u2026 319 \u2026 448 \u2026 3 \u2026 2.48 \u2026 1.28\u20134.79 \u2026 0.007\u201d (Table 2, row \u201c*6/*6\u201d under \u201cEfavirenz-induced liver injury\u201d, comparing CYP2B6 *6/*6 with CYP2B6 *1/*1)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*1",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "When CYP2B6*1/*6 and *6/*6 were combined, carriers had increased risk of efavirenz-induced liver injury versus CYP2B6*1/*1 (OR 1.94, 95% CI 1.24\u20133.01, P=0.003).",
              "Sentence": "Genotypes CYP2B6*1/*6 + *6/*6 Are Associated with increased susceptibility to efavirenz-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*1/*6 + *6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The pooled effects of *CYP2B6* polymorphisms on EFV-induced liver injury occurrences in PLHIV are summarized in Table [2](#Tab2) and illustrated in Fig. [2](#Fig2). Compared with normal metabolizers, *CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15\u20132.90), 2.48 (1.28\u20134.79), and 1.94 (1.24\u20133.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "| *1/*6 + *6/*6 | 0 | 0.56 | Fixed | 72 | 370 | 34 | 319 | 795 | 3 | 1.94 | 1.24\u20133.01 | 0.003 |",
                "Consequently, based on this premise, we conducted meta-analyses to verify the relationship between *CYP2B6* polymorphisms and their association with ARVDILI susceptibility. Our findings demonstrated that a genotype known as *CYP2B6*6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*6",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2B6*6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "When CYP2B6*1/*6 and *6/*6 were combined, carriers had increased risk of efavirenz-induced liver injury versus CYP2B6*1/*1 (OR 1.94, 95% CI 1.24\u20133.01, P=0.003).",
              "Sentence": "Genotypes CYP2B6*1/*6 + *6/*6 Are Associated with increased susceptibility to efavirenz-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*1/*6 + *6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The pooled effects of *CYP2B6* polymorphisms on EFV-induced liver injury occurrences in PLHIV are summarized in Table [2](#Tab2) and illustrated in Fig. [2](#Fig2). Compared with normal metabolizers, *CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15\u20132.90), 2.48 (1.28\u20134.79), and 1.94 (1.24\u20133.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "| *1/*6 + *6/*6 | 0 | 0.56 | Fixed | 72 | 370 | 34 | 319 | 795 | 3 | 1.94 | 1.24\u20133.01 | 0.003 |",
                "Consequently, based on this premise, we conducted meta-analyses to verify the relationship between *CYP2B6* polymorphisms and their association with ARVDILI susceptibility. Our findings demonstrated that a genotype known as *CYP2B6*6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*1",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Meta-analysis of 2 studies (African and Caucasian) showed CYP2B6*1/*6 heterozygotes had reduced risk of nevirapine-induced liver injury versus CYP2B6*1/*1 (OR 0.44, 95% CI 0.22\u20130.91, P=0.03).",
              "Sentence": "Genotype CYP2B6*1/*6 Is Associated with decreased susceptibility to nevirapine-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. [4](#Fig4)), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "On the contrary, in NVP\u2019s circumstance, the meta-analysis results showed that *CYP2B6* *1/*6 and a combination of *1/*6 and *6/*6 were dominantly found in the controls group, thus indicating that the poor metabolizer form of CYP2B6 may reduce the risk of ARVDILI.",
                "This meta-analysis illustrated that *CYP2B6 *6* and *1 was significantly associated with EFV-induced liver injury and NVP-induced liver injury in PLHIV, respectively."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*6",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2B6*6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Meta-analysis of 2 studies (African and Caucasian) showed CYP2B6*1/*6 heterozygotes had reduced risk of nevirapine-induced liver injury versus CYP2B6*1/*1 (OR 0.44, 95% CI 0.22\u20130.91, P=0.03).",
              "Sentence": "Genotype CYP2B6*1/*6 Is Associated with decreased susceptibility to nevirapine-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. [4](#Fig4)), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "On the contrary, in NVP\u2019s circumstance, the meta-analysis results showed that *CYP2B6* *1/*6 and a combination of *1/*6 and *6/*6 were dominantly found in the controls group, thus indicating that the poor metabolizer form of CYP2B6 may reduce the risk of ARVDILI.",
                "This meta-analysis illustrated that *CYP2B6 *6* and *1 was significantly associated with EFV-induced liver injury and NVP-induced liver injury in PLHIV, respectively."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*1",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Meta-analysis of 2 studies showed no significant association between CYP2B6*6/*6 homozygotes and risk of nevirapine-induced liver injury versus CYP2B6*1/*1 (OR 0.45, 95% CI 0.15\u20131.32, P=0.14).",
              "Sentence": "Genotype CYP2B6*6/*6 Is Not associated with susceptibility to nevirapine-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The association of *CYP2B6* with NVP-induced liver injury sensitivity in PLHIV is detailed in Table [2](#Tab2). Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. [4](#Fig4)), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)). However, there was no significant association between *CYP2B6* homozygous **6* with ARVDILI risk (Fig. [4](#Fig4)).",
                "| Nevirapine-induced liver injury |  |  |  |  |  |  |  |  |  |  |  |\n| *1/*6 | 0 | 0.97 | Fixed | 15 | 383 | 19 | 297 | 714 | 2 | 0.44 | 0.22\u20130.91 | 0.03 |\n| *6/*6 | 0 | 0.85 | Fixed | 4 | 102 | 19 | 297 | 533 | 2 | 0.45 | 0.15\u20131.32 | 0.14 |\n| *1/*6 + *6/*6 | 0 | 0.89 | Fixed | 19 | 485 | 19 | 297 | 820 | 2 | 0.42 | 0.21\u20130.84 | 0.01 |",
                "On the contrary, in NVP\u2019s circumstance, the meta-analysis results showed that *CYP2B6* *1/*6 and a combination of *1/*6 and *6/*6 were dominantly found in the controls group, thus indicating that the poor metabolizer form of CYP2B6 may reduce the risk of ARVDILI."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*6",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2B6*6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Meta-analysis of 2 studies showed no significant association between CYP2B6*6/*6 homozygotes and risk of nevirapine-induced liver injury versus CYP2B6*1/*1 (OR 0.45, 95% CI 0.15\u20131.32, P=0.14).",
              "Sentence": "Genotype CYP2B6*6/*6 Is Not associated with susceptibility to nevirapine-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The association of *CYP2B6* with NVP-induced liver injury sensitivity in PLHIV is detailed in Table [2](#Tab2). Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. [4](#Fig4)), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)). However, there was no significant association between *CYP2B6* homozygous **6* with ARVDILI risk (Fig. [4](#Fig4)).",
                "| Nevirapine-induced liver injury |  |  |  |  |  |  |  |  |  |  |  |\n| *1/*6 | 0 | 0.97 | Fixed | 15 | 383 | 19 | 297 | 714 | 2 | 0.44 | 0.22\u20130.91 | 0.03 |\n| *6/*6 | 0 | 0.85 | Fixed | 4 | 102 | 19 | 297 | 533 | 2 | 0.45 | 0.15\u20131.32 | 0.14 |\n| *1/*6 + *6/*6 | 0 | 0.89 | Fixed | 19 | 485 | 19 | 297 | 820 | 2 | 0.42 | 0.21\u20130.84 | 0.01 |",
                "On the contrary, in NVP\u2019s circumstance, the meta-analysis results showed that *CYP2B6* *1/*6 and a combination of *1/*6 and *6/*6 were dominantly found in the controls group, thus indicating that the poor metabolizer form of CYP2B6 may reduce the risk of ARVDILI."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*1",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "When CYP2B6*1/*6 and *6/*6 were combined, carriers had reduced risk of nevirapine-induced liver injury versus CYP2B6*1/*1 (OR 0.42, 95% CI 0.21\u20130.84, P=0.01).",
              "Sentence": "Genotypes CYP2B6*1/*6 + *6/*6 Are Associated with decreased susceptibility to nevirapine-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*1/*6 + *6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The association of *CYP2B6* with NVP-induced liver injury sensitivity in PLHIV is detailed in Table [2](#Tab2). Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. [4](#Fig4)), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "| Nevirapine-induced liver injury |  |  |  |  |  |  |  |  |  |  |  |\n| *1/*6 | 0 | 0.97 | Fixed | 15 | 383 | 19 | 297 | 714 | 2 | 0.44 | 0.22\u20130.91 | 0.03 |\n| *6/*6 | 0 | 0.85 | Fixed | 4 | 102 | 19 | 297 | 533 | 2 | 0.45 | 0.15\u20131.32 | 0.14 |\n| *1/*6 + *6/*6 | 0 | 0.89 | Fixed | 19 | 485 | 19 | 297 | 820 | 2 | 0.42 | 0.21\u20130.84 | 0.01 |",
                "Conversely, the mentioned genotype is also associated with a reduced risk in nevirapine-administered PLHIV."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*6",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2B6*6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 39604537,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "When CYP2B6*1/*6 and *6/*6 were combined, carriers had reduced risk of nevirapine-induced liver injury versus CYP2B6*1/*1 (OR 0.42, 95% CI 0.21\u20130.84, P=0.01).",
              "Sentence": "Genotypes CYP2B6*1/*6 + *6/*6 Are Associated with decreased susceptibility to nevirapine-induced liver injury in people with HIV infectious disease as compared to genotype CYP2B6*1/*1.",
              "Alleles": "*1/*6 + *6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "susceptibility to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The association of *CYP2B6* with NVP-induced liver injury sensitivity in PLHIV is detailed in Table [2](#Tab2). Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. [4](#Fig4)), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "| Nevirapine-induced liver injury |  |  |  |  |  |  |  |  |  |  |  |\n| *1/*6 | 0 | 0.97 | Fixed | 15 | 383 | 19 | 297 | 714 | 2 | 0.44 | 0.22\u20130.91 | 0.03 |\n| *6/*6 | 0 | 0.85 | Fixed | 4 | 102 | 19 | 297 | 533 | 2 | 0.45 | 0.15\u20131.32 | 0.14 |\n| *1/*6 + *6/*6 | 0 | 0.89 | Fixed | 19 | 485 | 19 | 297 | 820 | 2 | 0.42 | 0.21\u20130.84 | 0.01 |",
                "Conversely, the mentioned genotype is also associated with a reduced risk in nevirapine-administered PLHIV."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2B6*1, CYP2B6*6",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.8452593752493461,
      "total_samples": 4,
      "ground_truth_annotations": {
        "count": 4,
        "matched_count": 4,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8912208557128907,
            "annotation": {
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Toxicity",
              "Alleles": "*1/*6 + *6/*6",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2B6*1",
                "prediction": "CYP2B6*1/*6",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*6 + *6/*6",
                "prediction": "*1/*6 + *6/*6",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug-induced liver injury",
                "prediction": "Side Effect:Drug-induced liver injury",
                "score": 1.0,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "CYP2B6*1/*1",
                "score": 0.9122085571289062,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.89012810587883,
            "annotation": {
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Toxicity",
              "Alleles": "*1/*6 + *6/*6",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2B6*1",
                "prediction": "CYP2B6*1/*6",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*6 + *6/*6",
                "prediction": "*1/*6",
                "score": 0.9890725016593933,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug-induced liver injury",
                "prediction": "Side Effect:Drug-induced liver injury",
                "score": 1.0,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "CYP2B6*1/*1",
                "score": 0.9122085571289062,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8892210900783539,
            "annotation": {
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Toxicity",
              "Alleles": "*1/*6 + *6/*6",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2B6*1",
                "prediction": "CYP2B6*6/*6",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*6 + *6/*6",
                "prediction": "*6/*6",
                "score": 0.9800023436546326,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug-induced liver injury",
                "prediction": "Side Effect:Drug-induced liver injury",
                "score": 1.0,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "CYP2B6*1/*1",
                "score": 0.9122085571289062,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6892210900783539,
            "annotation": {
              "Variant/Haplotypes": "CYP2B6*1",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "Phenotype Category": "Toxicity",
              "Alleles": "*1/*6 + *6/*6",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2B6*1",
                "prediction": "CYP2B6*6/*6",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "nevirapine",
                "prediction": "nevirapine",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*6 + *6/*6",
                "prediction": "*6/*6",
                "score": 0.9800023436546326,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Not associated with",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Drug-induced liver injury",
                "prediction": "Side Effect:Drug-induced liver injury",
                "score": 1.0,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "CYP2B6*1/*1",
                "score": 0.9122085571289062,
                "match_status": "partial_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 4,
        "items": [
          {
            "variant": "*6/*6",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "*6/*6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": "39604537",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Combined analysis of CYP2B6*1/*6 heterozygotes and *6/*6 homozygotes versus CYP2B6*1/*1 normal metabolizers showed increased risk of efavirenz-induced liver injury in PLHIV (OR 1.94, 95% CI 1.24\u20133.01, P=0.003; 72 cases vs 34 cases and 370 controls vs 319 controls).",
              "Sentence": "CYP2B6*1/*6 + *6/*6 is associated with increased risk of Drug-induced liver injury when treated with efavirenz in people with Human immunodeficiency virus infection.",
              "Alleles": "*1/*6 + *6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Human immunodeficiency virus infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "39604537",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "Compared with normal metabolizers, *CYP2B6 *6* carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15\u20132.90), 2.48 (1.28\u20134.79), and 1.94 (1.24\u20133.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "| *1/*6 + *6/*6 | 0 | 0.56 | Fixed | 72 | 370 | 34 | 319 | 795 | 3 | 1.94 | 1.24\u20133.01 | 0.003 |",
                "Our findings demonstrated that a genotype known as *CYP2B6*6*, which is related with a decreased ability to metabolize drugs, was linked to an increased risk of ARVDILI in PLHIV patients who were using EFV."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6*1/*6",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2B6*1/*6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": "39604537",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Meta-analysis of 2 studies (African and Caucasian PLHIV) showed CYP2B6*1/*6 genotype was associated with decreased susceptibility to nevirapine-induced liver injury compared with CYP2B6*1/*1 (OR 0.44, 95% CI 0.22\u20130.91, P=0.03; 15 cases vs 19 cases and 383 controls vs 297 controls).",
              "Sentence": "CYP2B6*1/*6 is associated with decreased risk of Drug-induced liver injury when treated with nevirapine in people with Human immunodeficiency virus infection.",
              "Alleles": "*1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Human immunodeficiency virus infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "39604537",
              "Variant Annotation ID_norm": "4",
              "Citations": [
                "The association of *CYP2B6* with NVP-induced liver injury sensitivity in PLHIV is detailed in Table [2](#Tab2). Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. [4](#Fig4)), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "On the contrary, in NVP\u2019s circumstance, the meta-analysis results showed that *CYP2B6* *1/*6 and a combination of *1/*6 and *6/*6 were dominantly found in the controls group, thus indicating that the poor metabolizer form of CYP2B6 may reduce the risk of ARVDILI.",
                "In conclusion, our systematic review illustrated that *UGT1A1*, *CYP2B6*, and *ABCB1* were the most frequently studied genes. This meta-analysis illustrated that *CYP2B6 *6* and *1 was significantly associated with EFV-induced liver injury and NVP-induced liver injury in PLHIV, respectively."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "CYP2B6*1/*6",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2B6*1/*6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": "39604537",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Combined analysis of CYP2B6*1/*6 and *6/*6 genotypes versus CYP2B6*1/*1 showed decreased risk of nevirapine-induced liver injury in PLHIV (OR 0.42, 95% CI 0.21\u20130.84, P=0.01; 19 cases vs 19 cases and 485 controls vs 297 controls).",
              "Sentence": "CYP2B6*1/*6 + *6/*6 is associated with decreased risk of Drug-induced liver injury when treated with nevirapine in people with Human immunodeficiency virus infection.",
              "Alleles": "*1/*6 + *6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Human immunodeficiency virus infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "39604537",
              "Variant Annotation ID_norm": "6",
              "Citations": [
                "The association of *CYP2B6* with NVP-induced liver injury sensitivity in PLHIV is detailed in Table [2](#Tab2). Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. [4](#Fig4)), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "On the contrary, in NVP\u2019s circumstance, the meta-analysis results showed that *CYP2B6* *1/*6 and a combination of *1/*6 and *6/*6 were dominantly found in the controls group, thus indicating that the poor metabolizer form of CYP2B6 may reduce the risk of ARVDILI."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "*6/*6",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "*6/*6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": "39604537",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Combined analysis of CYP2B6*1/*6 and *6/*6 genotypes versus CYP2B6*1/*1 showed decreased risk of nevirapine-induced liver injury in PLHIV (OR 0.42, 95% CI 0.21\u20130.84, P=0.01; 19 cases vs 19 cases and 485 controls vs 297 controls).",
              "Sentence": "CYP2B6*1/*6 + *6/*6 is associated with decreased risk of Drug-induced liver injury when treated with nevirapine in people with Human immunodeficiency virus infection.",
              "Alleles": "*1/*6 + *6/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Drug-induced liver injury",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Human immunodeficiency virus infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2B6*1/*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "PMID_norm": "39604537",
              "Variant Annotation ID_norm": "6",
              "Citations": [
                "The association of *CYP2B6* with NVP-induced liver injury sensitivity in PLHIV is detailed in Table [2](#Tab2). Meta-analysis showed that *CYP2B6 *1/*6* allele and combination of **1/*6* + **6/*6* alleles were significantly associated with a reduction in susceptibility to NVP-induced liver injury, compared with normal metabolizer (Fig. [4](#Fig4)), with pooled OR and 95% CI of 0.44 (0.22\u20130.91) and 0.42 (0.21\u20130.84), respectively, as well as *P* value less than 0.05 (Table [2](#Tab2)).",
                "On the contrary, in NVP\u2019s circumstance, the meta-analysis results showed that *CYP2B6* *1/*6 and a combination of *1/*6 and *6/*6 were dominantly found in the controls group, thus indicating that the poor metabolizer form of CYP2B6 may reduce the risk of ARVDILI."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "study_parameters": {
      "score": 0.7909413039684295,
      "total_samples": 2,
      "ground_truth_annotations": {
        "count": 2,
        "matched_count": 2,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.6984860826941097,
            "annotation": {
              "Study Parameters ID": 1452721009,
              "Variant Annotation ID": 1452721001,
              "Study Type": "meta-analysis",
              "Study Cases": 795.0,
              "Study Controls": null,
              "Characteristics": "3 studies (Yimer 2011, Mugusi, Yimer 2012): DILI",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.003",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.94,
              "Confidence Interval Start": 1.24,
              "Confidence Interval Stop": 3.01,
              "Biogeographical Groups": "Sub-Saharan African"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452721009,
                "prediction": 3,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452721001,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "meta-analysis",
                "prediction": "meta-analysis",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 795.0,
                "prediction": 106,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 689,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "3 studies (Yimer 2011, Mugusi, Yimer 2012): DILI",
                "prediction": "Pooled African PLHIV on efavirenz; comparison of CYP2B6 *1/*6 + *6/*6 vs CYP2B6 *1/*1 for EFV-induced liver injury",
                "score": 0.8742634057998657,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.003",
                "prediction": "= 0.003",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.94,
                "prediction": 1.94,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.24,
                "prediction": 1.24,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.01,
                "prediction": 3.01,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Sub-Saharan African",
                "prediction": "African America/Afro-Caribbean",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6972926890148836,
            "annotation": {
              "Study Parameters ID": 1452720988,
              "Variant Annotation ID": 1452720980,
              "Study Type": "meta-analysis",
              "Study Cases": 504.0,
              "Study Controls": null,
              "Characteristics": "2 studies (Carr, Giacomelli): DILI",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.01",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.42,
              "Confidence Interval Start": 0.21,
              "Confidence Interval Stop": 0.84,
              "Biogeographical Groups": "Multiple groups, \"The meta-analysis of the link between CYP2B6 genotypes and EFV-induced liver injury was only derived from the African population, as well as NVP-induced liver injury were obtained from only African and Caucasian populations. "
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452720988,
                "prediction": 6,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452720980,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "meta-analysis",
                "prediction": "meta-analysis",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 504.0,
                "prediction": 38,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 782,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "2 studies (Carr, Giacomelli): DILI",
                "prediction": "Pooled African and European PLHIV on nevirapine; comparison of CYP2B6 *1/*6 + *6/*6 vs CYP2B6 *1/*1 for NVP-induced liver injury",
                "score": 0.8539757132530212,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.01",
                "prediction": "= 0.01",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.42,
                "prediction": 0.42,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.21,
                "prediction": 0.21,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.84,
                "prediction": 0.84,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups, \"The meta-analysis of the link between CYP2B6 genotypes and EFV-induced liver injury was only derived from the African population, as well as NVP-induced liver injury were obtained from only African and Caucasian populations. ",
                "prediction": "Multiple Groups",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 4,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 1,
              "Variant Annotation ID": null,
              "Study Type": "meta-analysis",
              "Study Cases": 106,
              "Study Controls": 689,
              "Characteristics": "Pooled African PLHIV on efavirenz; comparison of CYP2B6 *1/*6 vs CYP2B6 *1/*1 for EFV-induced liver injury",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.01",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.83,
              "Confidence Interval Start": 1.15,
              "Confidence Interval Stop": 2.9,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 2,
              "Variant Annotation ID": null,
              "Study Type": "meta-analysis",
              "Study Cases": 106,
              "Study Controls": 689,
              "Characteristics": "Pooled African PLHIV on efavirenz; comparison of CYP2B6 *6/*6 vs CYP2B6 *1/*1 for EFV-induced liver injury",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.007",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.48,
              "Confidence Interval Start": 1.28,
              "Confidence Interval Stop": 4.79,
              "Biogeographical Groups": "African America/Afro-Caribbean",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 4,
              "Variant Annotation ID": null,
              "Study Type": "meta-analysis",
              "Study Cases": 38,
              "Study Controls": 782,
              "Characteristics": "Pooled African and European PLHIV on nevirapine; comparison of CYP2B6 *1/*6 vs CYP2B6 *1/*1 for NVP-induced liver injury",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.03",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.44,
              "Confidence Interval Start": 0.22,
              "Confidence Interval Stop": 0.91,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 5,
              "Variant Annotation ID": null,
              "Study Type": "meta-analysis",
              "Study Cases": 38,
              "Study Controls": 782,
              "Characteristics": "Pooled African and European PLHIV on nevirapine; comparison of CYP2B6 *6/*6 vs CYP2B6 *1/*1 for NVP-induced liver injury",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.14",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.45,
              "Confidence Interval Start": 0.15,
              "Confidence Interval Stop": 1.32,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}